[go: up one dir, main page]

WO1997026912A3 - Anti-cd18 antibodies for use against stroke - Google Patents

Anti-cd18 antibodies for use against stroke Download PDF

Info

Publication number
WO1997026912A3
WO1997026912A3 PCT/US1997/000492 US9700492W WO9726912A3 WO 1997026912 A3 WO1997026912 A3 WO 1997026912A3 US 9700492 W US9700492 W US 9700492W WO 9726912 A3 WO9726912 A3 WO 9726912A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
mammal
use against
against stroke
antibody
Prior art date
Application number
PCT/US1997/000492
Other languages
French (fr)
Other versions
WO1997026912A2 (en
WO1997026912A9 (en
Inventor
Martin M Bednar
Cordell E Gross
G Roger Thomas
Original Assignee
Genentech Inc
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Univ Vermont filed Critical Genentech Inc
Priority to AT97903790T priority Critical patent/ATE222774T1/en
Priority to IL12525597A priority patent/IL125255A/en
Priority to CA2242414A priority patent/CA2242414C/en
Priority to JP52689497A priority patent/JP4864175B2/en
Priority to AU18273/97A priority patent/AU724449B2/en
Priority to EP97903790A priority patent/EP0877626B1/en
Priority to DE69714966T priority patent/DE69714966T2/en
Priority to DK97903790T priority patent/DK0877626T3/en
Publication of WO1997026912A2 publication Critical patent/WO1997026912A2/en
Publication of WO1997026912A3 publication Critical patent/WO1997026912A3/en
Publication of WO1997026912A9 publication Critical patent/WO1997026912A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
PCT/US1997/000492 1996-01-23 1997-01-11 Anti-cd18 antibodies for use against stroke WO1997026912A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT97903790T ATE222774T1 (en) 1996-01-23 1997-01-11 ANTIBODIES TO CD 18 FOR USE AGAINST BRAIN STROKE
IL12525597A IL125255A (en) 1996-01-23 1997-01-11 Anti-cd18 antibodies for treating stroke
CA2242414A CA2242414C (en) 1996-01-23 1997-01-11 Anti-cd18 antibodies for use against stroke
JP52689497A JP4864175B2 (en) 1996-01-23 1997-01-11 Anti-CD18 antibody for seizures
AU18273/97A AU724449B2 (en) 1996-01-23 1997-01-11 Anti-CD18 antibodies for use against stroke
EP97903790A EP0877626B1 (en) 1996-01-23 1997-01-11 Anti-cd18 antibodies for use against stroke
DE69714966T DE69714966T2 (en) 1996-01-23 1997-01-11 ANTIBODIES AGAINST CD 18 FOR USE AGAINST BRAIN SHOCK
DK97903790T DK0877626T3 (en) 1996-01-23 1997-01-11 Anti-CD18 antibodies for use against stroke

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58998296A 1996-01-23 1996-01-23
US08/589,982 1996-01-23

Publications (3)

Publication Number Publication Date
WO1997026912A2 WO1997026912A2 (en) 1997-07-31
WO1997026912A3 true WO1997026912A3 (en) 1997-10-09
WO1997026912A9 WO1997026912A9 (en) 1997-11-13

Family

ID=24360401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/000492 WO1997026912A2 (en) 1996-01-23 1997-01-11 Anti-cd18 antibodies for use against stroke

Country Status (13)

Country Link
EP (2) EP1297847A3 (en)
JP (1) JP4864175B2 (en)
AR (1) AR005535A1 (en)
AT (1) ATE222774T1 (en)
AU (1) AU724449B2 (en)
CA (1) CA2242414C (en)
DE (1) DE69714966T2 (en)
DK (1) DK0877626T3 (en)
ES (1) ES2183131T3 (en)
IL (1) IL125255A (en)
PT (1) PT877626E (en)
WO (1) WO1997026912A2 (en)
ZA (1) ZA97257B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
WO2000048681A2 (en) * 1999-02-17 2000-08-24 Genentech, Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP4210454B2 (en) 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
JP2004507448A (en) * 2000-03-18 2004-03-11 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド CD-18 binding antibody that suppresses stenosis-related diseases
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
EP1472275B1 (en) 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
HUE025101T2 (en) 2002-04-26 2016-02-29 Genentech Inc Non-affinity purification of proteins
HUE050171T2 (en) 2003-07-28 2020-11-30 Genentech Inc Reducing protein a leaching during protein a affinity chromatography
WO2005058251A2 (en) * 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
EP2481750A1 (en) * 2004-06-30 2012-08-01 Mayo Foundation for Medical Education and Research B7-DC binding antibody
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
FR2902799B1 (en) 2006-06-27 2012-10-26 Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
WO2009009523A2 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
PT2215117E (en) 2007-10-30 2015-04-01 Genentech Inc Antibody purification by cation exchange chromatography
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
SI2848625T1 (en) 2008-08-14 2019-11-29 Genentech Inc Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
MX2011002372A (en) 2008-09-10 2011-04-04 Genentech Inc Compositions and methods for the prevention of oxidative degradation of proteins.
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
KR101764449B1 (en) 2009-09-01 2017-08-02 제넨테크, 인크. Enhanced protein purification through a modified protein a elution
CA3027749A1 (en) 2010-03-22 2011-09-29 Junyan Ji Compositions and methods useful for stabilizing protein-containing formulations
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
JP2013525484A (en) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド Compositions and methods useful for reducing the viscosity of protein-containing formulations
KR101827855B1 (en) 2010-05-17 2018-02-12 이엠디 밀리포어 코포레이션 Stimulus responsive polymers for the purification of biomolecules
BR112012030197A2 (en) 2010-05-28 2015-09-29 Genentech Inc decreased lactate level and increased polypeptide production by downregulating lactate dehydrogenase and pyruvate dehydrogenase kinase expression.
AU2011270828B2 (en) 2010-06-24 2015-09-24 Genentech, Inc. Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
KR20130100125A (en) 2010-08-13 2013-09-09 제넨테크, 인크. Antibodies to il-1beta and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
KR101902225B1 (en) 2011-07-08 2018-09-28 이엠디 밀리포어 코포레이션 Improved depth filters for disposable biotechnological processes
MX360453B (en) 2011-12-22 2018-11-01 Genentech Inc Ion exchange membrane chromatography.
MX365947B (en) 2012-03-27 2019-06-19 Genentech Inc Improved harvest operations for recombinant proteins.
TR201810930T4 (en) 2012-05-18 2018-08-27 Genentech Inc High concentration monoclonal antibody formulations.
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
EP3777535A1 (en) 2014-07-09 2021-02-17 F. Hoffmann-La Roche AG Ph adjustment to improve thaw recovery of cell banks
AU2017242031B2 (en) 2016-03-29 2023-07-27 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
IL267439B2 (en) 2016-12-22 2023-02-01 Genentech Inc Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
HUE066560T2 (en) 2018-07-03 2024-08-28 Bristol Myers Squibb Co Recombinant protein production procedures
CN113166695A (en) 2018-10-10 2021-07-23 勃林格殷格翰国际公司 Method for membrane gas transfer in high density bioreactor culture
BR112021019612A2 (en) 2019-04-01 2021-11-30 Genentech Inc Formulations, container, article of manufacture, method for producing the formulation and method for inhibiting aggregation of a protein present in an aqueous solution
EP3953380A4 (en) 2019-04-12 2023-01-25 Geltor, Inc. Recombinant elastin and production thereof
KR20220039777A (en) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 Methods for improving protein productivity in fed-batch cell culture
KR20230073270A (en) 2020-09-22 2023-05-25 브리스톨-마이어스 스큅 컴퍼니 Methods of producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511156A (en) * 1992-07-16 1994-12-15 イコス　コーポレイション Relief of symptoms associated with inflammatory disease conditions
AU5732694A (en) * 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C. EIGENBROT ET AL.: "X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65.", PROTEINS: STRUCTURE, FUNCTION, AND GENETICS, vol. 18, no. 1, January 1994 (1994-01-01), NEW YORK, NY, USA, pages 49 - 62, XP000578098 *
E. MORI ET AL.: "Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons.", STROKE, vol. 23, no. 5, May 1992 (1992-05-01), DALLAS, TX, USA, pages 712 - 718, XP002036513 *
J. GARCIA ET AL.: "Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion.", AMERICAN JOURNAL OF PATHOLOGY, vol. 148, no. 1, January 1996 (1996-01-01), HAGERSTOWN, MD, USA, pages 241 - 248, XP002036510 *
M. BEDNAR ET AL.: "IB4, a monoclonal antibody against the CD18 adhesion complex of leukocytes, attenuates intracranial hypertension in a rabbit stroke model.", STROKE, vol. 23, no. 1, January 1992 (1992-01-01), DALLAS, TX, USA, pages 152, XP002036514 *
R. PEREZ ET AL.: "Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 270, no. 1 part 2, 1996, WASHINGTON, DC, USA, pages H53 - H64, XP002036511 *
T. AVERSANO ET AL.: "A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 25, no. 3, 1 March 1995 (1995-03-01), NEW YORK, NY, USA, pages 781 - 788, XP002036512 *

Also Published As

Publication number Publication date
AU1827397A (en) 1997-08-20
CA2242414C (en) 2012-01-03
AU724449B2 (en) 2000-09-21
EP0877626B1 (en) 2002-08-28
IL125255A (en) 2002-02-10
EP1297847A3 (en) 2003-05-07
IL125255A0 (en) 1999-03-12
ZA97257B (en) 1998-07-14
EP1297847A2 (en) 2003-04-02
DE69714966D1 (en) 2002-10-02
ATE222774T1 (en) 2002-09-15
CA2242414A1 (en) 1997-07-31
PT877626E (en) 2003-01-31
JP2000517289A (en) 2000-12-26
EP0877626A2 (en) 1998-11-18
DE69714966T2 (en) 2003-04-24
JP4864175B2 (en) 2012-02-01
DK0877626T3 (en) 2002-12-30
WO1997026912A2 (en) 1997-07-31
ES2183131T3 (en) 2003-03-16
AR005535A1 (en) 1999-06-23

Similar Documents

Publication Publication Date Title
WO1997026912A3 (en) Anti-cd18 antibodies for use against stroke
EP0701571A1 (en) USE OF FRAGMENTS OF ANTIBODIES IN THERAPY
EP1726276A3 (en) Vacuum assisted closure system with heating and cooling provision
EP1266965A3 (en) Recombinant antibodies for human therapy
EP0394946A3 (en) Human monoclonal antibody, and its production and use
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
WO1999033475A8 (en) Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
EP0741144A4 (en) ANTIANNEXIN-V MONOCLONAL ANTIBODY, PROCESS FOR PRODUCING THE ANTIBODY, AND USE OF THIS ANTIBODY
EP0717104A3 (en) Immunoassay for non-A, non-B hepatitis virus related antigens, monoclonal antibodies and hybridomas producing them
BG106226A (en) A blocking monoclinal antibody to vla-1 and its use for the treatment of inflammatory disorders
CA2136070A1 (en) Sequential Removal of Monosaccharides from the Reducing End of Oligosaccharides and Uses Thereof
CA2119128A1 (en) Alleviation of Symptoms Associated with Inflammatory Disease States
SE9201281D0 (en) NEW HUMAN MONOCLONAL ANTIBODIES, AND A METHOD FOR PREPARATION THEREOF
WO1991010735A3 (en) Human receptor of tsh. sequence coding for such receptor
ITRM940297A0 (en) "DEVICE FOR THE TRANSMISSION OF MANUAL ACCELERATION, BRAKING AND SIMILAR COMMANDS".
EP1438970A3 (en) Methods for inhibiting HIV associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells
FR2707234B1 (en) Structural element, in particular for a vehicle, comprising a relatively light and soft metal plate, and method relating thereto.
WO1991007986A8 (en) Method of treating septic shock
CA2213083A1 (en) Detection of antibody production
WO1999022766A3 (en) Use of anti-il-12 antibodies in transplantation rejection
EP0390460A3 (en) Giardia lambila-specific stool antigen, monospecific antibodies thereto, and method of diagnosis of giardiasis
WO1997002344A3 (en) Vaccine for infectious agents, composition for treating and preventing hiv infections
CA2259724A1 (en) Monoclonal antibody which is specific for activated coagulation factor vii, and its use
EP0084344A3 (en) Anti-urokinase monoclonal antibodies and process for preparing the same
FR2718134B1 (en) Method for inhibiting the oxidation and polymerization of furfural and its derivatives.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THERECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2242414

Country of ref document: CA

Ref country code: CA

Ref document number: 2242414

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997903790

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997903790

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997903790

Country of ref document: EP